3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment

3P Biopharmaceuticals (3P) and Norwegian biopharmaceutical company Nordic Nanovector have extended their collaboration agreement for the biopharmaceutical development of Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment

The non-Hodgkin lymphoma (NHL) is cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system.

3P and Nordic Nanovector started their collaboration in 2013 and successfully advanced Betalutin® project through these years.

The current agreement is consolidating the relationship describing how both companies will successfully progress the project up to the regulatory submission of the product including development, clinical supply and late-stage activities, such as process characterization and validation.

Our partnership with Nordic Nanovector is a great example of how together we can achieve more than planned and succeed in the late stage of Betalutin® development,” said Dámaso Molero, General Manager at 3P Biopharmaceuticals.

He also added, “this project demonstrates how we can bring together various parties to successfully reach the project goals by using complex technologies in this challenging project.

HH1 (Lilotomab) is a murine IgG1 antibody that targets the human glycoprotein CD37, which is found on the surface of B cells and B cell tumors.

The antibody is a component of Betalutin®, a radioimmunoconjugate molecule (RIC) which is being developed for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).

Related Content

Biovian and 3P Biopharmaceuticals join forces to create 3PBIOVIAN, a leading pan-European biologics CDMO

Published: 1st February 2024
Biovian and 3P Biopharmaceuticals (“3P”), two leading biologics Contract Development and Manufacturing Organizations (CDMOs), announced today their combination to establish a new pan-European leader in their field.
Read more

3P Biopharmaceuticals: building a legacy of innovation and excellence in biotechnology

Published: 20th December 2023
At the International Congress of High Impact Entrepreneurship, orchestrated by the European Business and Innovation Center of Navarra (CEIN), 3P Biopharmaceuticals (3P) emerges as the winner of the "Best Track Record in the CEIN incubators" award
Read more

3P Biopharmaceuticals and the University of Navarra bring the Neanderthal world and biomedicine to the public in a successful event.

Published: 19th October 2023
This afternoon Pamplona became the epicentre of knowledge and innovation in the field of biomedicine, thanks to the event "Exploring our shared legacy between Neanderthals and Sapiens: challenges and uncertainties of future biomedicine", organized by 3P Biopharmaceuticals in collaboration with the Faculty of Pharmacy and Nutrition of the University of Navarra.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.